Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Inventory: 2023-2025

Historic Change in Inventory for Tg Therapeutics (TGTX) over the last 3 years, with Sep 2025 value amounting to -$8.7 million.

  • Tg Therapeutics' Change in Inventory fell 442.32% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year increase of 23.77%. This contributed to the annual value of $66.9 million for FY2024, which is 80.98% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Change in Inventory is -$8.7 million, which was down 141.86% from -$3.6 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Change in Inventory peaked at $46.3 million during Q1 2025, and registered a low of -$8.7 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Inventory was $2.6 million (2024), whereas its average is $12.5 million.
  • In the last 5 years, Tg Therapeutics' Change in Inventory surged by 350.78% in 2024 and then slumped by 442.32% in 2025.
  • Quarterly analysis of 3 years shows Tg Therapeutics' Change in Inventory stood at $5.5 million in 2023, then surged by 350.78% to $24.8 million in 2024, then tumbled by 442.32% to -$8.7 million in 2025.
  • Its Change in Inventory was -$8.7 million in Q3 2025, compared to -$3.6 million in Q2 2025 and $46.3 million in Q1 2025.